Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BY 4.0Internal and Emergency Medicine

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity

2 more authors
8 affiliations
  1. 1Geriatrics Division, “Renato Dulbecco” University Hospital of Catanzaro, 88100 Catanzaro, Italy
  2. 2Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open, University of Rome, Rome, Italy
  3. 3IRCCS San Raffaele, Rome, Italy
  4. 4Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy
  5. 5Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
  6. 6Research Center for the Prevention and Treatment of Metabolic Diseases (CR‑METDIS), University Magna Græcia, 88100 Catanzaro, Italy
  7. 7Division of Cardiology, Department of Medicine, Karolinska Institutet, and Heart and Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden
  8. 8Department of Clinical and Molecular Medicine, University of Rome-Sapienza, 00185 Rome, Italy

Abstract

Heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes mellitus are common in elderly patients and are associated with an increased risk of cognitive impairment (CoI). In these patients, the protective metabolic and vascular effects of glucagon-like peptide−1 receptor agonists (GLP-1 RAs) are well established. The aim of this study was to evaluate effects of one-year treatment with oral semaglutide versus DPP-4 inhibitors (DPP4i), as an add-on to the hypoglycaemic therapy, on the incidence of CoI in patients with HFpEF, obesity, and type 2 diabetes. 246 elderly outpatients were recruited and divided into two groups (oral semaglutide vs. DPP4i), accurately matched for age, sex, and body mass index (BMI). At one-year follow-up, 106 new cases of CoI were observed in the entire study population (43.1 events/100 patients/year). A significant difference was found between the two groups: 33 cases with oral semaglutide (26.8 events/100 patients/year) versus 73 cases with DPP4i (59.3 events/100 patients/year), p<0.0001. Logistic regression analysis indicated a 77% reduced risk of incident CoI with oral semaglutide compared to DPP4i. In elderly patients with HFpEF, obesity and type 2 diabetes, oral semaglutide seems to have a positive effect in reducing the incidence of cognitive impairment.

Graphical Abstract:

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11739-026-04499-4.

Related

  1. The Efficacy of Group Cognitive Behavioural Therapy for Reducing Attention-Deficit Hyperactivity Disorder Symptoms and Impairment in Indian University Students: A Randomized Controlled Trial
    Dr Kadim Lovakumari, Prof Tosendra Dwivedi
    PsyArXivPreprintCC BY 4.0Full textPsychiatry & mental healthOSF
  2. Impact of co-administration of proton pump inhibitors on efficacy and safety of oral semaglutide in patients with type 2 diabetes: a single-center retrospective study
    Tasuku Yokoyama, Tomonobu Uchino, Yasuharu Yazawa +2
    Journal of Pharmaceutical Health Care and SciencesPeer-reviewedCC BY 4.0Full textEndocrinology & metabolismPMC
  3. Effects of a cognitive training program on cancer-related cognitive impairment in breast cancer patients in active treatment: a randomized controlled trial
    Juan Luis Sánchez-González, Samuel Jiménez-Sánchez, Celia Sánchez-Gómez +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Association of conventional and non-conventional lipid profile with cognitive impairment among type 2 diabetic patients
    Behnaz Esmaeili, Elahe Hesari, Kazem Khalaji +6
    Journal of Diabetes and Metabolic DisordersPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  5. Pilot clinical study of Taxifolin Aqua effect in patients with amnestic mild cognitive impairment
    Elena V. Ponomareva, Natalya D. Selezneva, Irina S. Boksha +6
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
BibTeX
@article{armentaro2026oral,
  title = {{Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity}},
  author = {Giuseppe Armentaro and Cristiana Vitale and Velia Cassano and Marilisa Panza and Ilaria Gareri and Maria Mirabelli and Elena Succurro and Francesco Andreozzi and Antonio Brunetti and Gianluigi Savarese and Maurizio Volterrani and Giorgio Sesti and Giuseppe Massimo Claudio Rosano and Angela Sciacqua},
  journal = {Internal and Emergency Medicine},
  year = {2026},
  month = aug,
  doi = {10.1007/s11739-026-04499-4},
  url = {https://doi.org/10.1007/s11739-026-04499-4},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity
AU  - Giuseppe Armentaro
AU  - Cristiana Vitale
AU  - Velia Cassano
AU  - Marilisa Panza
AU  - Ilaria Gareri
AU  - Maria Mirabelli
AU  - Elena Succurro
AU  - Francesco Andreozzi
AU  - Antonio Brunetti
AU  - Gianluigi Savarese
AU  - Maurizio Volterrani
AU  - Giorgio Sesti
AU  - Giuseppe Massimo Claudio Rosano
AU  - Angela Sciacqua
PY  - 2026
DA  - 2026/08/20
JO  - Internal and Emergency Medicine
DO  - 10.1007/s11739-026-04499-4
UR  - https://doi.org/10.1007/s11739-026-04499-4
AB  - Heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes mellitus are common in elderly patients and are associated with an increased risk of cognitive impairment (CoI). In these patients, the protective metabolic and vascular effects of glucagon-like peptide−1 receptor agonists (GLP-1 RAs) are well established. The aim of this study was to evaluate effects of one-year treatment with oral semaglutide versus DPP-4 inhibitors (DPP4i), as an add-on to the hypoglycaemic therapy, on the incidence of CoI in patients with HFpEF, obesity, and type 2 diabetes. 246 elderly outpatients were recruited and divided into two groups (oral semaglutide vs. DPP4i), accurately matched for age, sex, and body mass index (BMI). At one-year follow-up, 106 new cases of CoI were observed in the entire study population (43.1 events/100 patients/year). A significant difference was found between the two groups: 33 cases with oral semaglutide (26.8 events/100 patients/year) versus 73 cases with DPP4i (59.3 events/100 patients/year), p<0.0001. Logistic regression analysis indicated a 77% reduced risk of incident CoI with oral semaglutide compared to DPP4i. In elderly patients with HFpEF, obesity and type 2 diabetes, oral semaglutide seems to have a positive effect in reducing the incidence of cognitive impairment.  Graphical Abstract:  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11739-026-04499-4.
SN  - 1828-0447
SN  - 1970-9366
ER  -